In situ Formed Implants, Based on PLGA and Eudragit Blends, for Novel Florfenicol Controlled Release Formulations

Drug controlled release technologies (DCRTs) represent an opportunity for designing new therapies. Main objectives are dose number optimization and secondary effects reduction to improve the level of patient/client acceptance. The present work studies DCRTs based in blended polymeric implants for si...

Full description

Saved in:
Bibliographic Details
Published in:Journal of pharmaceutical sciences 2021-03, Vol.110 (3), p.1270-1278
Main Authors: Karp, Federico, Turino, Ludmila N., Helbling, Ignacio M., Islan, German A., Luna, Julio A., Estenoz, Diana A.
Format: Article
Language:English
Subjects:
Antibiotics
Autocatalytic effect
Biocompatible polymers
Biocompatible solvent
Controlled release
Drug delivery systems
Eudragit polymers
Florfenicol
PLGA
Polymers
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Drug controlled release technologies (DCRTs) represent an opportunity for designing new therapies. Main objectives are dose number optimization and secondary effects reduction to improve the level of patient/client acceptance. The present work studies DCRTs based in blended polymeric implants for single dose and long-term therapies of florfenicol (FF), a broad spectrum antibiotic. Polymers used were PLGA and Eudragit E100/S100 types. Eudragit/PLGA and FF/PLGA ratios were the main studied factors in terms of encapsulation efficiencies (EEs) and drug release profiles. In addition, morphological and physicochemical characterization were carried out. EEs were of 50–100% depending on formulation composition, and the FF releasing rate was increased or diminished when E100 or S100 were added, respectively. PLGA hydrolytic cleavage products possibly affect Eudragit solubility and matrix stability. Different mathematical models were used for better understanding and simulating release processes. Implants maintained the antimicrobial activity against Pseudomonas aeruginosa up to 12 days on agar plates. The developed DCRTs represents a suitable alternative for florfenicol long-term therapies.
ISSN:0022-3549
1520-6017
DOI:10.1016/j.xphs.2020.11.006